This clinical trial is focused on patients undergoing surgery for obesity, specifically looking at how to manage postoperative pain without relying heavily on opioids, which are strong pain-relieving drugs. The study will explore the effects of an opioid-sparing care pathway, which means using alternative methods and medications to reduce the need for opioids. The medications being studied include esketamine, dexmedetomidine, lidocaine hydrochloride monohydrate, and remifentanil hydrochloride. These medications are used in different forms, such as solutions for injection or infusion, to help manage pain and aid recovery after surgery.
The purpose of the study is to compare this new approach to the traditional opioid-based treatment in terms of pain relief, recovery after surgery, and overall health outcomes. Participants will receive either the new treatment or the conventional treatment, which may include a placebo. The study will monitor various aspects of recovery, including pain levels, the amount of opioids used, and the patient’s ability to recover and return to normal activities. The study will also look at how this approach affects the patient’s confidence in managing unexpected events and their quality of life over time.
Throughout the study, participants will be observed at different intervals, such as immediately after surgery, during their hospital stay, and at several points after discharge, including 3, 6, 12, and 24 months later. The goal is to see if the opioid-sparing approach can provide effective pain management and improve recovery without the side effects associated with high opioid use. This research aims to offer better pain management strategies for patients undergoing obesity surgery, potentially leading to improved health outcomes and quality of life.
Sweden 
